<title>Seattle Genetics, Inc. (SGEN) News & Commentary

AOL.com
About Us
Follow Us :

DJIA	15,406.47	71.19	0.46%
NASDAQ	3,509.77	13.34	0.38%
S&P 500	1,673.08	6.79	0.41%

Recent Quotes Watchlist Portfolios

+ Add to Portfolio

Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker B

Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker Buys ACADIA

5/20/2013 by Nasdaq

Tackling Cancer: Leukemia's Biggest Current and Upcoming Players

Cancer research is big business, and it pays to know where research dollars are headed.

5/19/2013 by DailyFinance

SGEN's Adcetris under FDA Review - Analyst Blog

5/16/2013 by Zacks

Seattle Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

5/15/2013 by Seeking Alpha

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by t

5/14/2013 by DailyFinance

Seattle Genetics Announces ADCETRIS Supplemental BLA Accepted for Filing by the FDA

5/14/2013 by Benzinga

Seattle Genetics to Present at Upcoming Investor Conferences

5/9/2013 by DailyFinance

The True Value Of Seattle Genetics

5/9/2013 by Seeking Alpha

Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog

Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog

5/8/2013 by Zacks

Seattle Genetics Management Discusses Q1 2013 Results - Earnings Call Transcript

5/7/2013 by Seeking Alpha

See More Articles...